Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Melatonin Use Linked to Reduced Risk of AMD
A recent study published online in JAMA Ophthalmology suggests that melatonin use is associated with a decreased risk of both the development and progression of age-related macular degeneration (AMD). Investigating the Association: A Retrospective Cohort Study Hejin Jeong, from the…
Australia’s 2nd Generation Bionic Eye Shows Promise in RP
Australia’s second-generation bionic eye has demonstrated “substantial improvement” in functional vision, daily activities, and quality of life for four participants over a period of more than two and a half years, according to the results of the first clinical trial.…
Skye Bioscience’s Next Steps After Glaucoma Trial Disappointment
Skye Bioscience’s phase 2a clinical trial of its SBI-100 ophthalmic emulsion in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) has failed to meet its primary endpoint for lowering intraocular pressure (IOP). Consequently, the company announced its decision…
What Is Lens Replacement Surgery?
Lens replacement surgery, also known as Refractive Lens Exchange (RLE) or Clear Lens Extraction (CLE), is a procedure designed to improve vision by replacing the eye’s natural lens with an artificial one. This surgery is particularly beneficial for those who…
Your Complete Guide to Cataract Surgery
Cataract surgery is a safe, effective procedure that improves vision by removing cloudy lenses from the eyes and replacing them with artificial lenses. As technology advances and techniques improve, understanding the nuances of cataract surgery is crucial for anyone considering…
Melt Pharmaceuticals Launches MELT-300 Phase 3 Program
Melt Pharmaceuticals has completed the dosing of its first patient in its phase 3 program for MELT-300, marking a crucial step in evaluating the safety and efficacy of this pioneering product. MELT-300 is a non-intravenous, non-opioid tablet comprising fixed doses…
Harrow Reveals 52-Week Data for Vevye ESSENCE-2 Study
Harrow, a leading pharmaceutical company, has revealed the encouraging results from its ESSENCE‑2 open-label extension (OLE) clinical study for Vevye (cyclosporine ophthalmic solution) 0.1%, a novel treatment for dry eye disease (DED). Study Design and Outcomes: ESSENCE-2 OLE Analysis The…
Eversight Partners with LighTopTech to Improve Eye Imaging
Eversight has partnered up with LighTopTech to elevate the standards of imaging modalities for eye tissues. This ambitious partnership, spanning over four years, sets out to redefine the landscape of ocular imaging in both clinical and research domains. LighTopTech’s OCX…
CorneaGen Launches CTAK for Keratoconus Patients
CorneaGen, a leading provider of ocular tissue, announced the commercial launch of Corneal Tissue Addition for Keratoplasty (CTAK), a novel solution for corneal contouring in keratoconic eyes. Developed in collaboration with CTAK LLC and Ziemer, CTAK offers patient-ready, gamma-irradiated sterile…
BIOPHTA Secures €6.5M to Advance Eye Disease Therapy
BIOPHTA, a preclinical biotech company, has successfully closed a Seed round, raising €6.5 million to advance its pioneering technology into clinical development for the treatment of glaucoma and macular edema. This significant funding injection, led by prominent European venture capital…